{
    "table": "| Methods                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Participants                                                                                                                                                                                                                                                                       | Interventions                                                                                                                                                                                                                                                                                                                     | Outcomes                                                                                                                                              | Notes                                                                                                  |\n|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------|:-------------------------------------------------------------------------------------------------------|\n| Retrospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 92 women                                                                                                                                                                                                                                                                           | Prog \u00b1 Met from 1999\u20132018                                                                                                                                                                                                                                                                                                         | Complete response (CR), Time to CR, Disease recurrence, Live-birth pregnancy rate                                                                     | Prog-Met therapy not supported, <20% achieved live-birth pregnancy, majority required ART.             |\n| Retrospective study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Patients aged 20\u201342 with CEH or grade 1 EC                                                                                                                                                                                                                                         | Oral medroxyprogesterone acetate (250\u2013500 mg/day) or megestrol acetate (160\u2013480 mg/day) for at least 6 months                                                                                                                                                                                                                     | 74% achieved complete response                                                                                                                        | Obese patients had lower complete response rate.                                                       |\n| Retrospective analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 63 patients (42 with EC; 21 with AEH)                                                                                                                                                                                                                                              | MPA (400 mg/day) and metformin (750\u20132,250 mg/day)                                                                                                                                                                                                                                                                                 | CR rates at 6, 8\u20139, and 12 months were 60%, 84%, and 90%, respectively                                                                                | BMI \u226525 kg/m2 had significantly better prognoses than BMI <25 kg/m2.                                   |\n| Randomized controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Women with endometrial hyperplasia                                                                                                                                                                                                                                                 | Randomly assigned to LNG-IUS, oral MPA 10 mg for 10 days per cycle, or continuous oral MPA 10 mg daily for 6 months                                                                                                                                                                                                               | Therapy response, withdrawals, demographic data                                                                                                       | NR                                                                                                     |\n| Controlled, single-blinded, prospective cohort study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 16 EAH patients aged \u226445 years with at least one metabolic syndrome criterion                                                                                                                                                                                                      | MA group: 160 mg of MA daily; MET group: 160 mg of MA daily plus 0.5 g of metformin thrice daily                                                                                                                                                                                                                                  | Response assessment by histological examination of D&C specimens after 12 weeks                                                                       | NR                                                                                                     |\n| Women under 45 years with complex atypical hyperplasia or grade one endometrial cancer were treated with oral progestin. Data was collected from medical records and telephone questionnaires. Time until complete response and time until recurrence were analyzed. Cumulative incidence functions were used to estimate event probability over time. 44 patients were included, with a median age of 36.5 years. 55% achieved a complete response to progestin treatment, with a median time to response of 5.7 months. 54% of those with a complete response experienced a recurrence, with a median time to recurrence of 3.5 years. 55% of patients underwent hysterectomy, and 25% underwent fertility treatment with varying outcomes. | NR                                                                                                                                                                                                                                                                                 | NR                                                                                                                                                                                                                                                                                                                                | NR                                                                                                                                                    | NR                                                                                                     |\n| Randomized controlled phase II study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Patients with primary grade 1 endometrioid endometrial carcinoma without myometrial invasion; 18\u201345 years old; no signs of suspicious myometrial invasion or extrauterine metastasis; normal uterine size; strong desire to preserve fertility; no contraindications for pregnancy | MA alone (160 mg, orally, daily) vs. MA (160 mg, orally, daily) combined with LNG-IUS (containing LNG 52 mg) insertion                                                                                                                                                                                                            | 16-week CR rate, 32-week CR rate, CR time, 1-year cumulative recurrence rate, 2-year cumulative recurrence rate, 1-year cumulative pregnancy rate     | NR                                                                                                     |\n| Randomized controlled phase II study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Patients with atypical endometrial hyperplasia                                                                                                                                                                                                                                     | Oral MA + LNG-IUS, LNG-IUS alone, oral MA alone                                                                                                                                                                                                                                                                                   | 16-week CR rate, 32-week CR rate, 1-year recurrence rate, 2-year recurrence rate, 1-year pregnancy rate                                               | Study conducted from July 21, 2017, to June 18, 2020.                                                  |\n| Randomised controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 150 patients (18\u201345 years old) with primary AEH or well-differentiated EEC                                                                                                                                                                                                         | MA group (n = 74) and MA plus metformin group (n = 76)                                                                                                                                                                                                                                                                            | Primary outcome: Cumulative complete response (CR) rate within 16 weeks of treatment (16w-CR rate); Secondary outcome: 30w-CR rate and adverse events | NR                                                                                                     |\n| Retrospective analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29 patients younger than 45 years with early well-differentiated endometrioid adenocarcinoma of the uterus (EC) or complex atypical hyperplasia (CAH)                                                                                                                              | Combination of intramuscular injections of GnRHa every 4 weeks with the levonorgestrel intrauterine hormonal system (Mirena; Bayer Health Care Pharmaceutical Inc, Wayne, NY) was inserted. Eleven patients were treated with the combination of intramuscular injections of GnRHa every 4 weeks with oral letrozole 2.5 mg daily | Complete response (CR) after GnRHa combination treatment, time to CR, pregnancy outcomes                                                              | Successful fertility-preserving treatment for women with CAH and EC who desire fertility preservation. |\n| Clinicopathological data review                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 148 patients with stage IA, grade 1, endometrioid adenocarcinoma                                                                                                                                                                                                                   | Daily oral medroxyprogesterone acetate (MPA) or megestrol acetate (MA)                                                                                                                                                                                                                                                            | 77.7% showed complete response (CR) to progestin treatment; 30.4% experienced recurrence                                                              | NR                                                                                                     |"
}